Company Filing History:
Years Active: 2024
Title: Innovations in Immunomodulatory Medicines by Wenhui Qi
Introduction
Wenhui Qi is a notable inventor based in Xi'an, China. He has made significant contributions to the field of immunomodulatory medicines, particularly in the treatment of neuromyelitis optica and immune rejection after skin transplantation. His innovative work has the potential to enhance clinical applications and improve patient outcomes.
Latest Patents
Wenhui Qi holds a patent for the "Applications of ellagic acid in preparation of immunomodulatory medicines for treatment of neuromyelitis optica or immune rejection after skin transplantation." This patent describes the use of ellagic acid and its metabolic derivative, urolithin, in developing an immunomodulatory medicine. The research utilizes classical animal models of autoimmunity and immunoregulation, such as experimental autoimmune encephalomyelitis and neuromyelitis optica mouse models. The experiments demonstrate that ellagic acid and its derivatives significantly improve recovery from autoimmune conditions and inhibit inflammatory cell infiltration into the central nervous system.
Career Highlights
Wenhui Qi is affiliated with Shaanxi Normal University, where he conducts research and develops innovative solutions in immunology. His work has garnered attention for its clinical application value and development prospects. The experiments conducted under his guidance have shown promising results in ameliorating conditions such as experimental colitis and preventing graft rejection.
Collaborations
Wenhui Qi collaborates with esteemed colleagues, including Yuan Zhang and Xing Li. Their combined expertise enhances the research efforts and contributes to the advancement of immunomodulatory therapies.
Conclusion
Wenhui Qi's innovative research in immunomodulatory medicines showcases the potential of ellagic acid and its derivatives in treating autoimmune diseases and improving immune tolerance. His contributions to the field are significant and hold promise for future clinical applications.